Intermittent administration of valacyclovir is effective for prevention of herpes zoster events in patients with multiple myeloma treated with bortezomib

姚一芸; 唐勇; 庄衍; 汪蕾; 邹丽芳; 朱琦

doi:10.3969/j.issn.1007-3969.2014.07.009

您当前的位置：

首页 >

文章列表页 >

Intermittent administration of valacyclovir is effective for prevention of herpes zoster events in patients with multiple myeloma treated with bortezomib

更新时间：2025-12-31

- Intermittent administration of valacyclovir is effective for prevention of herpes zoster events in patients with multiple myeloma treated with bortezomib
- China Oncology Vol. 24, Issue 7, Pages: 525-528(2014)
- 作者机构：
  
  上海交通大学医学院附属第九人民医院血液内科,上海,200011
- 作者简介：
- 基金信息：
- DOI：10.3969/j.issn.1007-3969.2014.07.009
  CLC：
- Published Online：29 July 2014，
  
  Published：29 July 2014
- 稿件说明：
移动端阅览
姚一芸,唐勇,庄衍,汪蕾,邹丽芳,朱琦. 间断口服伐昔洛韦预防多发性骨髓瘤患者应用硼替佐米致带状疱疹的临床观察[J]. 中国癌症杂志, 2014, 24(7): 525-528.

姚一芸, 唐勇, 庄衍, et al. Intermittent administration of valacyclovir is effective for prevention of herpes zoster events in patients with multiple myeloma treated with bortezomib[J]. China Oncology, 2014, 24(7): 525-528.
姚一芸,唐勇,庄衍,汪蕾,邹丽芳,朱琦. 间断口服伐昔洛韦预防多发性骨髓瘤患者应用硼替佐米致带状疱疹的临床观察[J]. 中国癌症杂志, 2014, 24(7): 525-528. DOI： 10.3969/j.issn.1007-3969.2014.07.009.

姚一芸, 唐勇, 庄衍, et al. Intermittent administration of valacyclovir is effective for prevention of herpes zoster events in patients with multiple myeloma treated with bortezomib[J]. China Oncology, 2014, 24(7): 525-528. DOI： 10.3969/j.issn.1007-3969.2014.07.009.

摘要

背景与目的：随着硼替佐米成功用于多发性骨髓瘤的治疗，药物导致带状疱疹激活现象受到关注。本研究探讨硼替佐米治疗期间伐昔洛韦不同用药方法预防带状疱疹的效果。方法：31例多发性骨髓瘤患者随机分成伐昔洛韦间断应用组和连续应用组，分别观察2组患者带状疱疹发生情况、药物不良反应、抗病毒治疗费用及情绪状态。结果：2组患者治疗期间均未合并带状疱疹，未发生3级以上药物不良反应，间断用药组的抗病毒费用支出低于连续治疗组。患者情绪取决于基础疾病疗效，既往治疗不理想的连续用药组患者有焦虑抑郁表现。结论：伐昔洛韦间断应用能够有效预防硼替佐米治疗期间多发性骨髓瘤患者带状疱疹发生。

Abstract

Background and purpose: Herpes zoster is a common adverse event associated with the use of bortezomib. The objective of this study was to evaluate the efficacy of different therapeutic regimens of valacyclovir prophylaxis: continuously administration and intermittent administration. Methods: We retrospectively analyzed the efficacy

side effects

expense of valacyclovir and emotional states of 31 patients with multiple myeloma who received bortezomib and valacyclovir prophylaxis. Among them

14 patients underwent continuously administration of valacyclovir

the other 17 patients underwent intermittent administration. Continuously administration was defined as daily oral valacyclovir 600 mg without cessation during entire period of bortezomib treatment. Intermittent administration was defined as patients received valacyclovir at a dose of 600 mg daily during chemotherapy

while discontinue valacyclovir at the intermission time of bortezomib treatment. Results: There were no herpes zoster in patients of 2 arms. Adverse events over grade 3 associated with valacyclovir were not observed. Intermittent administration of valacyclovir showed a superiority of economic benefit. The emotional status were depended on the therapeutic effects of multiple myeloma. For those relapsed or refractory patients

continuously administration of valacyclovir might aggravate depression and anxiety. Conclusion: Intermittent administration of valacyclovir at a dose of 600 mg daily appears to be an effective prophylaxis for herpes zoster in patients receiving bortezomib.

关键词

Keywords

references

Views

2798

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Experimental study on montelukast sodium inducing apoptosis in multiple myeloma cells via targeting intracellular USP2 protein

Experimental study on sinomenine derivative modulating chemokine receptor in multiple myeloma cells

Experimental study on cAMP analogue combined with arsenic trioxide inducing apoptosis in multiple myeloma cells

Experimental study on forskolin combined with bortezomib inducing apoptosis in bortezomibresistant multiple myeloma cells

Multiple myeloma: from diagnosis to staging

Related Author

Qi ZHU

Yingli WU

Yiyun YAO

Yong TANG

Yingying WANG

Chengrong DU

Shenaonan JU

Qi ZHU

Related Institution

Department of Oral and Maxillofacial-Head and Neck Oncology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine; College of Stomatology, Shanghai Jiao Tong University; National Center for Stomatology; National Clinical Research Center for Oral Diseases; Shanghai Key Laboratory of Stomatology; Shanghai Research Institute of Stomatology

Department of Pathophysiology, Key Laboratory of Cell Differentiation and Apoptosis of the Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine

Department of Hematology/Oncology, Shanghai Second People’s Hospital

Department of Oral and Maxillofacial-Head and Neck Oncology, Shanghai Ninth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Department of Hematology/Oncology, Shanghai Ninth People’s Hospital Huangpu Branch Affiliated to Shanghai Jiao Tong University School of Medicine

AI问答

⁰